Antibody-drug conjugate · Cytotoxic, directed at HER2 (ERBB2) and DNA topoisomerase I (TOP1) · developed by BioNTech
Trastuzumab pamirtecan is an antibody-drug conjugate in which the anti-HER2 antibody trastuzumab is linked by a cleavable linker to the topoisomerase I inhibitor P1003. After binding HER2 on tumor cells and being internalized, the payload is released and inhibits DNA topoisomerase 1, causing cell cycle arrest and apoptosis. It is studied in breast cancer and endometrial cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06340568 | Phase 3 | Endometrial Cancer | Recruiting | BNTX |
| NCT06018337 | Phase 3 | Metastatic Breast Cancer | Active not recruiting | BNTX |
| NCT06827236 | Phase 1/2 | Locally Advanced Breast Cancer | Recruiting | BNTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Endometrial CancerLocally Advanced Breast CancerMetastatic Breast CancerUnresectable Breast Carcinoma
See BNTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
BNTX catalysts and pipeline →